Diabetes Mellitus Type 2
Conditions
Brief summary
This is a randomised, placebo-controlled, double-blind, parallel-group, international, multicentre, Phase IV study to investigate the effects of dapagliflozin on cardiac substrate uptake, myocardial efficiency and myocardial contractile work in T2D patients. Eligible subjects with T2D before randomisation and fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomised in a 1:1 ratio to dapagliflozin 10 mg or placebo once daily and treated for six weeks. The study includes five visits.
Detailed description
The following will be assessed at Baseline and at the end of the treatment period; 1. MRI scanning in order to assess cardiac function and morphology. The MRI scanning will be made after fasting for at least 6 hours in the same time of day at all visits. The cardiac MRI examination will be performed in accordance with a pre-defined MRI protocol, with the total scan time at each visit estimated to 45 minutes. Images from all sites will be analyzed centrally at the core-lab using a dedicated software package and certified analysts. 2. CT-PET scanning will be made to assess myocardial function and metabolism, as well as fatty acid metabolism in brain, liver and kidney cortex. The CT-PET scanning will be made after a fast as well as abstinence from nicotine, alcohol and caffeine for at least 6 hours at the same time of day at all visits. * A cardiac 11C-Acetate PET/CT examination is performed (IV 400 MBq 11C-Acetate). * A cardiac 18F-FTHA PET/CT examination is performed (IV 150 MBq 18F-FTHA). The subject is further examined by PET/CT over the liver, kidney cortex and brain (in this order) for uptake of 18F-FTHA. Arterialized venous samples are acquired throughout to assess P-NEFA and 18F-FTHA metabolism by metabolite analysis
Interventions
DRUGdapagliflozin
dapagliflozin 10mg
DRUGplacebo
placebo to match dapagliflozin
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses. * Females or males ≥40 years up to 75 years of age. * Individuals with type 2 diabetes diagnosed for at least 6 months based on the American Diabetes Association standards (ADA, 2017) and on stable dose of metformin for at least 6 weeks prior to screening and HbA1c at screening visit of ≥42 mmol/mol (6.0%) and ≤75 mmol/mol (9.0%) measured at local hospital laboratory. * No significant signs or symptoms of coronary artery disease or, if known coronary artery disease, currently free of symptoms and a) all major epicardial vessels with \<50% stenosis within 12 months prior to screening, or b) if revascularized with all major epicardial vessels with \<50% remaining stenosis after stenting or bypass surgery procedure determined between 3 and 12 months prior to screening. * Normal left ventricular ejection fraction (≥50%) assessed within 1 year prior to informed consent, and if applicable, after most recent acute episode of coronary artery syndrome, or at screening visit. * Body mass index (BMI) ≥ 25 kg/m2.
Exclusion criteria
* Blood pressure at screening that would require a change in blood pressure treatment over the study period or any of the following: systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg. * History of stroke or other clinically significant cerebrovascular disease. * Any of the following cardiovascular diseases known within 3 months prior to signing the consent at enrolment: 1. Atrial fibrillation, or other unstable or severe arrhythmia affecting heart function 2. Unstable heart failure or any heart failure with NYHA class III and IV 3. Significant valvular disease 4. Significant peripheral artery disease * Planned cardiac surgery or angioplasty within 3 months from enrolment. * Clinical diagnosis of type 1 diabetes, maturity onset diabetes of the young (MODY), secondary diabetes or diabetes insipidus. * Verified body weight variability of \>3 kg during the 3 proceeding months before screening. * Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma). * Patients with severe hepatic impairment (Child-Pugh class C). * Unstable or rapidly progressing renal disease. * Clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. * Ongoing treatment with other antidiabetic drugs than metformin. * Ongoing treatment with loop diuretics. * Ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents. * Contraindications to dapagliflozin therapy. * Ongoing treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except for T2D. * Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 1 month prior to screening. * Estimated Glomerular Filtration Rate (eGFR) \<45 mL/min/1.73 m2. * Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study treatment intake. * Any condition when MRI and CT-PET is contraindicated such as, but not limited to, having a metallic implant (such as pacemaker or cochlear implant), permanent make up, claustrophobia or BMI ≥40 kg/m2). * Involvement in the planning and/or conduct of the study. * Plasma donation within one month of screening or any blood donation/blood loss \>450 mL during the 3 months prior to screening. * Women who has a positive pregnancy test at enrolment or randomization, or are breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adjusted Mean Change From Baseline in Global Longitudinal Strain of the Left Ventricle (GLSLV) at End of Treatment. | Baseline (Day 1) and end of treatment (Day 42) | Patients underwent magnetic resonance imaging (MRI) examination to determine the GLSLV, which is expressed as a percentage. The least square mean (LSM) change from baseline estimates were generated from an analysis of covariance (ANCOVA) model with treatment and baseline value of the endpoint as covariates. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adjusted Mean Change From Baseline in Myocardial Efficiency at End of Treatment. | Baseline (Day 1) and end of treatment (Day 42) | A clinical radiologic assessment of acquired computed tomography and positron emission tomography (CTPET)-\[11C\]-acetate images was performed to determine myocardial efficiency. The myocardial efficiency calculation was based on an estimate of energy used for producing LV contractile work (mean arterial pressure (MAP) x stroke volume (SV) x heart rate (HR) / myocardial mass) compared to the total cardiac work (calculated based on the total myocardial oxygen consumption per myocardial mass) and is expressed as a percentage. The LSM change from baseline estimates, were generated from an ANCOVA model with treatment and baseline value of the endpoint as covariates. |
Countries
Finland, Sweden
Participant flow
Recruitment details
Fifty three patients with type 2 diabetes and on a stable dose of metformin for at least 6 weeks were enrolled in 1 study center in Sweden and 1 center in Finland. The first patient was enrolled on 28 February 2018 and the last patient's last visit was on 19 March 2019.
Pre-assignment details
Eligible patients were aged between 40 and 75 years, had type 2 diabetes for at least 6 months and had no significant coronary artery disease symptoms. Patients were randomized in a 1:1 ratio, to receive 10 milligram (mg) dapagliflozin or placebo.
Participants by arm
| Arm | Count |
|---|---|
| Dapagliflozin 10 mg Patients were randomized to receive an oral dose of 10 mg dapagliflozin, once daily, for 6 weeks. | 27 |
| Placebo Patients were randomized to receive an oral dose of placebo (to match 10 mg dapagliflozin), once daily, for 6 weeks. | 26 |
| Total | 53 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Did not receive treatment | 1 | 0 |
| Overall Study | In receipt of disallowed medication | 1 | 0 |
Baseline characteristics
| Characteristic | Dapagliflozin 10 mg | Placebo | Total |
|---|---|---|---|
| Age, Customized <65 years | 12 Participants | 11 Participants | 23 Participants |
| Age, Customized ≥65 years | 15 Participants | 15 Participants | 30 Participants |
| Race/Ethnicity, Customized White | 27 Participants | 26 Participants | 53 Participants |
| Sex: Female, Male Female | 8 Participants | 15 Participants | 23 Participants |
| Sex: Female, Male Male | 19 Participants | 11 Participants | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 26 | 0 / 26 |
| other Total, other adverse events | 0 / 26 | 0 / 26 |
| serious Total, serious adverse events | 0 / 26 | 0 / 26 |
Outcome results
Primary
Adjusted Mean Change From Baseline in Global Longitudinal Strain of the Left Ventricle (GLSLV) at End of Treatment.
Patients underwent magnetic resonance imaging (MRI) examination to determine the GLSLV, which is expressed as a percentage. The least square mean (LSM) change from baseline estimates were generated from an analysis of covariance (ANCOVA) model with treatment and baseline value of the endpoint as covariates.
Time frame: Baseline (Day 1) and end of treatment (Day 42)
Population: Patients in the MRI evaluable analysis set who, as per clinical judgment, had fasted and abstained from products containing nicotine, caffeine and alcohol for at least 6 hours prior to both of the times when MRI measurements were taken.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Dapagliflozin 10 mg | Adjusted Mean Change From Baseline in Global Longitudinal Strain of the Left Ventricle (GLSLV) at End of Treatment. | 0.30769 Percentage of GLSLV |
| Placebo | Adjusted Mean Change From Baseline in Global Longitudinal Strain of the Left Ventricle (GLSLV) at End of Treatment. | -0.00352 Percentage of GLSLV |
Comparison: Difference in LSM (Placebo-Dapagliflozin 10 mg)p-value: 0.50495% CI: [-0.619, 1.24141]ANCOVA
Secondary
Adjusted Mean Change From Baseline in Myocardial Efficiency at End of Treatment.
A clinical radiologic assessment of acquired computed tomography and positron emission tomography (CTPET)-\[11C\]-acetate images was performed to determine myocardial efficiency. The myocardial efficiency calculation was based on an estimate of energy used for producing LV contractile work (mean arterial pressure (MAP) x stroke volume (SV) x heart rate (HR) / myocardial mass) compared to the total cardiac work (calculated based on the total myocardial oxygen consumption per myocardial mass) and is expressed as a percentage. The LSM change from baseline estimates, were generated from an ANCOVA model with treatment and baseline value of the endpoint as covariates.
Time frame: Baseline (Day 1) and end of treatment (Day 42)
Population: Patients in the CTPET-\[11C\]-acetate evaluable analysis set who, as per clinical judgment, had fasted and abstained from products containing nicotine, caffeine and alcohol for at least 6 hours prior to both of the times when CTPET-\[11C\]-acetate measurements were taken.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Dapagliflozin 10 mg | Adjusted Mean Change From Baseline in Myocardial Efficiency at End of Treatment. | -0.71474 Percentage of Myocardial Efficiency |
| Placebo | Adjusted Mean Change From Baseline in Myocardial Efficiency at End of Treatment. | -2.46443 Percentage of Myocardial Efficiency |
Comparison: Difference in LSM (Placebo - Dapagliflozin 10 mg)p-value: 0.42795% CI: [-2.64837, 6.14775]ANCOVA